Advisory Committee; Transmissible Spongiform Encephalopathies Advisory Committee; Termination, 37153 [2016-13705]

Download as PDF Federal Register / Vol. 81, No. 111 / Thursday, June 9, 2016 / Rules and Regulations § 416.926a [Amended] 4. Amend § 416.926a by removing paragraph (m)(1) and redesignating paragraphs (m)(2) through (6) as (m)(1) through (5). ■ [FR Doc. 2016–13275 Filed 6–8–16; 8:45 am] BILLING CODE 4191–02–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Part 14 [Docket No. FDA–2016–N–0001] Advisory Committee; Transmissible Spongiform Encephalopathies Advisory Committee; Termination AGENCY: Food and Drug Administration, HHS. ACTION: Final rule. The Food and Drug Administration (FDA) is announcing the termination of the Transmissible Spongiform Encephalopathies Advisory Committee. This document removes the Transmissible Spongiform Encephalopathies Advisory Committee from the Agency’s list of standing advisory committees. DATES: This rule is effective June 9, 2016. SUMMARY: rmajette on DSK2TPTVN1PROD with RULES FOR FURTHER INFORMATION CONTACT: Bryan Emery, Division of Scientific Advisors and Consultants, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 6132, Silver Spring, MD 20993–0002, 240– 402–8054, FAX: 301–595–1307, or bryan.emery@fda.hhs.gov. SUPPLEMENTARY INFORMATION: The Transmissible Spongiform Encephalopathies Advisory Committee (the Committee) was established on June 9, 1995 (60 FR 31311, June 14, 1995; 21 CFR 14.100 erroneously lists the date of establishment as June 21, 1995). The Committee reviews and evaluates available scientific data concerning the safety of products that may be a risk for transmission of spongiform encephalopathies having an impact on the public health as determined by the Commissioner of Food and Drugs. The Committee makes recommendations to the Commissioner regarding the regulation of such products. In recent years, the number of issues requiring Committee advice has declined, and the Committee has met very infrequently. Therefore, the effort and expense of maintaining this advisory committee is no longer justified. Any relevant VerDate Sep<11>2014 14:17 Jun 08, 2016 Jkt 238001 Transmissible Spongiform Encephalopathy issues in the future could be addressed by the Agency’s other advisory committees, such as the Agency’s Blood Products Advisory Committee, with additional augmentation of expertise by appropriate subject matter experts serving as temporary members on the committee. The Committee is no longer needed and will be terminated on June 9, 2016. Under 5 U.S.C. 553(b)(3)(B) and (d) and 21 CFR 10.40 (d) and (e), the Agency finds good cause to dispense with notice and public comment procedures and to proceed to an immediate effective date on this rule. Notice and public comment and a delayed effective date are unnecessary and are not in the public interest as this final rule merely removes the name of the Transmissible Spongiform Encephalopathies Advisory Committee from the list of standing advisory committees in 21 CFR 14.100. Therefore, the Agency is amending 21 CFR 14.100(b) as set forth in the regulatory text of this document. List of Subjects in 21 CFR Part 14 Administrative practice and procedure, Advisory committees, Color additives, Drugs, Radiation protection. Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR part 14 is amended as follows: PART 14—PUBLIC HEARING BEFORE A PUBLIC ADVISORY COMMITTEE 1. The authority citation for part 14 continues to read as follows: ■ Authority: 5 U.S.C. App. 2; 15 U.S.C. 1451–1461, 21 U.S.C. 41–50, 141–149, 321– 394, 467f, 679, 821, 1034; 28 U.S.C. 2112; 42 U.S.C. 201, 262, 263b, 264; Pub. L. 107–109; Pub. L. 108–155. § 14.100 [Amended] 2. In § 14.100, redesignate paragraph (b)(5) as (b)(4) and remove paragraph (b)(6). ■ Dated: June 6, 2016. Jill Hartzler Warner, Associate Commissioner for Special Medical Programs. [FR Doc. 2016–13705 Filed 6–8–16; 8:45 am] PO 00000 Frm 00033 Fmt 4700 DEPARTMENT OF THE INTERIOR Office of Natural Resources Revenue 30 CFR Part 1241 [Docket No. ONRR–2016–0002; DS63644000 DR2PS0000.CH7000167D0102R2] RIN 1012–AA17 Civil Monetary Penalties Inflation Adjustment Office of the Secretary, Office of Natural Resources Revenue, Interior. ACTION: Interim final rule. AGENCY: The Office of Natural Resources Revenue (ONRR) publishes this interim final rule to adjust the amount of our civil monetary penalties (CMPs) for inflation with an initial ‘‘catch-up’’ adjustment under the Federal Civil Penalties Inflation Adjustment Act Improvements Act of 2015 and Office of Management and Budget (OMB) guidance. DATES: This rule is effective July 11, 2016. Comments will be accepted until August 8, 2016. ADDRESSES: You may submit comments to ONRR by one of the following three methods. (Please reference the Regulation Identifier Number (RIN) 1012–AA17 in your comments.). See also Public Availability of Comments under Procedural Requirements. 1. Electronically, go to www.regulations.gov. In the entry titled ‘‘Enter Keyword or ID,’’ enter ‘‘ONRR– 2016–0002,’’ and then click ‘‘Search.’’ Follow the instructions to submit public comments. ONRR will post all comments. 2. Mail comments to Luis Aguilar, Regulatory Specialist, ONRR, P.O. Box 25165, MS 64400B, Denver, Colorado 80225. 3. Hand-carry comments, or use an overnight courier service to the Office of Natural Resources Revenue, Building 53, Entrance E–20, Denver Federal Center, West 6th Ave. and Kipling St., Denver, Colorado 80225. FOR FURTHER INFORMATION CONTACT: For comments or questions on procedural issues, contact Luis Aguilar, Regulatory Specialist, by telephone at (303) 231– 3418 or email to luis.aguilar@onrr.gov. For questions on technical issues, contact Geary Keeton, Chief of Enforcement, by telephone at (303) 231– 3096 or email to geary.keeton@onrr.gov. SUPPLEMENTARY INFORMATION: SUMMARY: I. Background II. Method of Calculation III. Summary of Final Rule IV. Procedural Requirements BILLING CODE 4164–01–P Sfmt 4700 37153 E:\FR\FM\09JNR1.SGM 09JNR1

Agencies

[Federal Register Volume 81, Number 111 (Thursday, June 9, 2016)]
[Rules and Regulations]
[Page 37153]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-13705]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 14

[Docket No. FDA-2016-N-0001]


Advisory Committee; Transmissible Spongiform Encephalopathies 
Advisory Committee; Termination

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the 
termination of the Transmissible Spongiform Encephalopathies Advisory 
Committee. This document removes the Transmissible Spongiform 
Encephalopathies Advisory Committee from the Agency's list of standing 
advisory committees.

DATES: This rule is effective June 9, 2016.

FOR FURTHER INFORMATION CONTACT: Bryan Emery, Division of Scientific 
Advisors and Consultants, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 71, Rm. 6132, Silver Spring, MD 20993-0002, 240-
402-8054, FAX: 301-595-1307, or bryan.emery@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: The Transmissible Spongiform 
Encephalopathies Advisory Committee (the Committee) was established on 
June 9, 1995 (60 FR 31311, June 14, 1995; 21 CFR 14.100 erroneously 
lists the date of establishment as June 21, 1995). The Committee 
reviews and evaluates available scientific data concerning the safety 
of products that may be a risk for transmission of spongiform 
encephalopathies having an impact on the public health as determined by 
the Commissioner of Food and Drugs. The Committee makes recommendations 
to the Commissioner regarding the regulation of such products. In 
recent years, the number of issues requiring Committee advice has 
declined, and the Committee has met very infrequently. Therefore, the 
effort and expense of maintaining this advisory committee is no longer 
justified. Any relevant Transmissible Spongiform Encephalopathy issues 
in the future could be addressed by the Agency's other advisory 
committees, such as the Agency's Blood Products Advisory Committee, 
with additional augmentation of expertise by appropriate subject matter 
experts serving as temporary members on the committee.
    The Committee is no longer needed and will be terminated on June 9, 
2016.
    Under 5 U.S.C. 553(b)(3)(B) and (d) and 21 CFR 10.40 (d) and (e), 
the Agency finds good cause to dispense with notice and public comment 
procedures and to proceed to an immediate effective date on this rule. 
Notice and public comment and a delayed effective date are unnecessary 
and are not in the public interest as this final rule merely removes 
the name of the Transmissible Spongiform Encephalopathies Advisory 
Committee from the list of standing advisory committees in 21 CFR 
14.100.
    Therefore, the Agency is amending 21 CFR 14.100(b) as set forth in 
the regulatory text of this document.

List of Subjects in 21 CFR Part 14

    Administrative practice and procedure, Advisory committees, Color 
additives, Drugs, Radiation protection.

    Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs, 21 CFR part 
14 is amended as follows:

PART 14--PUBLIC HEARING BEFORE A PUBLIC ADVISORY COMMITTEE

0
1. The authority citation for part 14 continues to read as follows:

    Authority:  5 U.S.C. App. 2; 15 U.S.C. 1451-1461, 21 U.S.C. 41-
50, 141-149, 321-394, 467f, 679, 821, 1034; 28 U.S.C. 2112; 42 
U.S.C. 201, 262, 263b, 264; Pub. L. 107-109; Pub. L. 108-155.


Sec.  14.100  [Amended]

0
2. In Sec.  14.100, redesignate paragraph (b)(5) as (b)(4) and remove 
paragraph (b)(6).

    Dated: June 6, 2016.
Jill Hartzler Warner,
Associate Commissioner for Special Medical Programs.
[FR Doc. 2016-13705 Filed 6-8-16; 8:45 am]
 BILLING CODE 4164-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.